Rimonabant Hydrochloride
Added to RFQ
For Research & Analytical Purposes. Not for Personal use.
Packaging & Handling
Indicative product packaging is shown for visual reference. Actual packaging may vary based on pack size, quantity, storage condition and shipping requirements.
Documentation Available
Detailed specifications, certificates, and supporting documents are available upon request.
Detailed specifications, certificates, and supporting documents are available upon request.
Storage: Refer MSDS for complete information.
Hazard: Refer MSDS for accurate information.
Rimonabant Hydrochloride Product Information
Rimonabant Hydrochloride is listed under API and is intended for analytical research, quality control and pharmaceutical reference standard applications. It is associated with Rimonabant. The product is supplied by Clearsynth under CAT No. CS-O-30748.
Clearsynth provides this compound for research and analytical use, with product information including CAS number, molecular formula, molecular weight and product enquiry details.
Technical Data
Product Name
Rimonabant Hydrochloride
CAS No.
158681-13-1
CAT No.
CS-O-30748
HSN Code
38229010
Country of Origin
Can be shipped from India, Canada and USA
Molecular Formula
C22H22Cl4N4O
Molecular Weight
500.25
Category
API Family
Storage Condition
Refer MSDS for complete information.
Hazard Compound
Refer MSDS for accurate information.
Description
Regulatory Description
Rimonabant Hydrochloride is supplied with detailed characterization data compliant with regulatory guideline. Rimonabant Hydrochloride can be used for analytical method development, method validation (AMV), Quality Control (QC) application for Abbreviated New Drug Application (ANDA), or during commercial production of Rimonabant.
Overview
Rimonabant is an anorectic anti-obesity drug produced and marketed by Sanofi-Aventis. It is an inverse agonist for the cannabinoid receptor CB1. Its main avenue of effect is reduction in appetite.
Synonyms
Rimonabant Hydrochloride
Application Notes
Rimonabant is an anorectic anti-obesity drug produced and marketed by Sanofi-Aventis. It is an inverse agonist for the cannabinoid receptor CB1. Its main avenue of effect is reduction in appetite.
Product Applications & Regulatory Search Terms
Useful product, supplier and regulatory search terms for this reference standard.